Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
14 mai 2024 10h05 HE
|
Affimed N.V.
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated...